$0.98
-0.00 (-0.32%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where CGTX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
12 interventional · 1 expanded access · 5 with posted results
Held by 3 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, GABELLI FUNDS LLC, Qube Research & Technologies Ltd) · FINRA short interest 21.1 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's DiseaseNCT05531656Change from baseline in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) scale.Randomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: CT1812, Placebo | Early Alzheimer's Disease | 540 | 2027-05-31 | in 284 d | 2026-08-10 |
| Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).NCT05893537Change from baseline in Geographic Atrophy (GA) lesion area over 104 weeks in the study eye.Randomized · Quadruple-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: The trial was closed as part of a strategic business decision. | Drug: Active Comparator CT1812, Placebo Comparator | Age-Related Macular Degeneration | 100 | 2025-03-04actual | — | 2025-04-16 |
| Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy BodiesNCT05225415results2026-03-12Number of Study Participants With at Least One Mild, Moderate, or Severe Treatment Emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: CT1812 | Dementia With Lewy Bodies | 130 | 2024-11-25actual | — | 2026-03-12 |
| A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.NCT03507790results2025-08-11Number of Study Participants With at Least One Mild, Moderate, or Severe Treatment Emergent Adverse Events (TEAEs)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: CT1812, Placebo | Mild to Moderate Alzheimer's Disease | 153 | 2024-05-29actual | — | 2025-08-11 |
| Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEGNCT04735536results2024-11-29Number of TEAEs, Related TEAEs, SAEs, and Related SAEsRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: CT1812 · Other: Placebo | Alzheimer Disease | 16 | 2023-04-26actual | — | 2024-11-29 |
| Study to Assess the Pharmacokinetics of CT1812 in Older Healthy VolunteersNCT05248672Pharmacokinetics (PK) in plasmaRandomized · Quadruple-masked · Basic science | Phase 1 | Completed | Drug: CT1812 | Alzheimer Disease | 35 | 2022-06-01actual | — | 2023-04-12 |
| Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male SubjectsNCT05225389results2023-07-21Plasma CT1812 Concentration at 96 Hours TimepointOpen-label · Basic scienceStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: 300 mg [C14] CT1812 | Alzheimer Disease | 8 | 2022-01-17actual | — | 2023-07-21 |
| Effect of CT1812 Treatment on Brain Synaptic DensityNCT03493282results2023-03-01Number of TEAEs, Related TEAEs, SAEs, and Related SAEsRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: Active Treatment- CT1812 100 mg, Active Treatment- CT1812 300 mg, Placebo | Alzheimer Disease | 43 | 2020-10-16actual | — | 2023-09-07 |
| Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's DiseaseNCT03522129Measuring the displacement of Amyloid beta oligomers into cerebrospinal fluid (CSF)Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: CT1812, Placebo | Alzheimer Disease | 3 | 2019-02-06actual | — | 2022-01-12 |
| Clinical Trial of CT1812 in Mild to Moderate Alzheimer's DiseaseNCT02907567Incidence and review of Treatment Emergent Adverse EventsRandomized · Quadruple-masked · Treatment | Phase 1/2 | Completed | Drug: CT1812, Placebo | Alzheimer's Disease | 19 | 2017-08-24actual | — | 2018-07-26 |
| Drug Interaction Study of CT1812 in Healthy VolunteersNCT03716427Area under the plasma-concentration time curve of CT1812 (Day 6) compared to the baseline values (Day -2)Open-label · Treatment | Phase 1 | Completed | Drug: CT1812, tolbutamide, dextromethorphan, Omeprazole, midazolam | Healthy Volunteers | 16 | 2016-12-27actual | — | 2018-10-23 |
| Ascending Dose Study of CT1812 in Healthy VolunteersNCT02570997Incidence and review of Treatment Emergent Adverse Events [Safety and Tolerability]Randomized · Quadruple-masked · Basic science | Phase 1 | Completed | Drug: CT1812, Placebo | Cognitive Impairment | 80 | May 2016actual | — | 2016-09-07 |
| Expanded Access Program for CT1812 (Zervimesine)NCT06961760expanded access | — | No longer available | Drug: zervimesine | Dementia With Lewy Bodies | — | — | — | 2026-05-28 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19